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1. Chemistry  
 
Normal phase TLCs were carried out on pre-coated silica plates (Kieselgel 60 F254, BDH) with 
visualisation via U.V. light (UV254/365 nm) and/or ninhydrin solution. Flash chromatography was 
performed using Combiflash Companion Rf (commercially available from Teledyne ISCO) and 
prepacked silica gel columns purchased from Teledyne ISCO. Mass-directed preparative HPLC 
separations were performed using a Waters HPLC (2545 binary gradient pumps, 515 HPLC make up 
pump, 2767 sample manager) connected to a Waters 2998 photodiode array and a Waters 3100 mass 
detector. Preparative HPLC separations were performed with a Gilson HPLC (321 pumps, 819 
injection module, 215 liquid handler/injector) connected to a Gilson 155 UV/vis detector. On both 
instruments, HPLC chromatographic separations were conducted using Waters XBridge C18 columns, 
19 x 100 mm, 5 um particle size; using 0.1% ammonia in water (solvent A) and acetonitrile (solvent 
B) or 0.1% formic acid in water (solvent A) and acetonitrile (solvent B) as mobile phase. 1H NMR 
spectra were recorded on a Bruker Avance DPX 500 spectrometer (1H at 500.1 MHz, 13C at 125 MHz 
19F at 470.5 MHz), or a Bruker Avance DPX 300 (1H at 300 MHz). Chemical shifts (δ) are expressed in 
ppm recorded using the residual solvent as the internal reference in all cases. Signal splitting patterns 
are described as singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m), broad (br), or a 
combination thereof. Coupling constants (J) are quoted to the nearest 0.5 Hz. Low resolution 
electrospray (ES) mass spectra were recorded on a Bruker Daltonics MicrOTOF mass spectrometer, 
run in positive mode. LC-MS analysis and chromatographic separation were conducted with a Brucker 
Daltonics MicrOTOF mass spectrometer or an Agilent Technologies 1200 series HPLC connected to 
an Agilent Technologies 6130 quadrupole LC/MS, where both instruments were connected to an 
Agilent diode array detector or on Bruker MicrOTOF II focus ESI Mass Spectrometer connected in 
parallel to Dionex Ultimate 3000 RSLC system with diode array detector. HPLC chromatographic 
separations were conducted using a Waters XBridge C18 column, 2.1 x 50mm, 3.5 μm particle size or 
Waters XSelect 2.1 x 30mm, 2.5 μm particle size. The compounds were eluted with a gradient of 5 to 
95% acetonitrile/water +0.1% Ammonia or +0.1% formic acid.  
 
Unless otherwise stated herein reactions have not been optimised. Solvents and reagents were 
purchased from commercial suppliers and used without further purification. Dry solvents were 
purchased in sure sealed bottles stored over molecular sieves. 
 
The preparations and compounds have been named using the ChemDraw Ultra 12.0 naming 
application which is commercially available from the CambridgeSoft Corporation.  
 
4-Oxochromene-2-carboxylic acid and 6-fluoro-4-oxo-chromene-2-carboxylic acid are commercially 
available from TCI-UK or Fluorochem. 
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N-(cyclohexylmethyl) 4-oxo-4H-chromene-2-carboxamide (2) 
 
4-oxochromene-2-carboxylic acid (0.5 g, 2.6 mmol) was dissolved in DMF (6 ml) and diisopropylethyl 
amine (0.34 g, 2.6 mmol) was added. The reaction mixture was then cooled to 0 oC with an ice water 
bath and a solution of PyBOP in DCM (6 ml) was added. The mixture was stirred at 0oC for 30 min 
then cyclohexylmethanamine (298 mg, 2.6 mmol) was added and the reaction was stirred at room 
temperature for 4h. After solvent evaporation the crude material was purified by flash column 
chromatography eluting with 40 % EtOAc in heptane. The desired fractions were concentrated to 
dryness to give the desired product (256 mg, 35% yield). ¹H NMR (500 MHz, d6-DMSO) 9.10 (1H, t, 
J=6.0 Hz), 8.06 (1H, dd, J=1.5, 7.9 Hz), 7.92 - 7.88 (1H, m), 7.76 (1H, d, J=8.2 Hz), 7.55 (1H, dd, J=7.1, 
7.1 Hz), 6.83 (1H, s), 3.16 (2H, dd, J=6.6, 6.6 Hz), 1.71 (4H, t, J=13.5 Hz), 1.65 - 1.56 (2H, m), 1.25 - 1.14 
(3H, m), 0.99 - 0.92 (2H, m) ppm. 13C NMR (500 MHz, d6-DMSO) δ 177.81, 159.51, 156.33, 155.61, 
135.40, 126.46, 125.39, 124.13, 119.32, 110.88, 45.90, 37.82, 30.93, 26.46, 25.84 ppm. LC-MS (ESI) 
m/z 286 [M+H]+. HRMS (ES+) calculated for C17H20NO3 [M+H]+= 286.1438, observed for C17H20NO3 
[M+H]+= 286.1448. 
 
N-(cyclohexylmethyl)-6-fluoro-4-oxo-chromene-2-carboxamide (3). 
 
6-fluoro-4-oxo-chromene-2-carboxylic acid (0.13 mg, 0.62 mmol) was dissolved in DCM (5 ml) and 
diisopropylethyl amine (0.81 g, 0.62 mmol) was added. The reaction mixture was then cooled in an 
ice bath and a solution of PyBOP (0.32 g, 0.62 mmol) in DCM (2 ml) was added. The mixture was 
stirred at 0oC for 30 min and then the corresponding amine was added. The reaction mixture was 
stirred at room temperature for 4h. The crude was partitioned between DCM (10 ml) and brine (5 
ml). The compound was precipitated from methanol and DMSO. Compound was filtered and dried to 
obtained N-(cyclohexylmethyl)-6-fluoro-4-oxo-chromene-2-carboxamide (20 mg, 10 % yield) as an 
off-white solid. 1H NMR (500 MHz, CDCl3) δ 7.87 (dd, J=3.1, 8.1 Hz, 1H), 7.56 (dd, J=4.1, 9.2 Hz, 1H), 
7.47 (ddd, J=3.1, 7.4, 9.2 Hz, 1H), 7.17 (s, 1H), 6.88 (s, 1H), 3.36 (dd, J=6.6, 6.6 Hz, 2H), 1.84 - 1.75 (m, 
3H), 1.74 - 1.62 (m, 2H), 1.56 (s, 1H), 1.33 - 1.18 (m, 3H), 1.08 - 0.99 (m, 2H) ppm. 13C NMR (500 MHz, 
d6-DMSO) δ 177.23, 160.67, 159.34, 156.55, 152.06, 125.39, 123.65, 122.18, 110.12, 109.96, 45.91, 
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37.83, 30.92, 26.45, 25.84 ppm. LC-MS (ESI) m/z 304 (M+H)+. HRMS (ES+) calculated for C17H18FNO3 
[M+H]+= 304.1343, observed for C17H18FNO3 [M+H]+= 304.1349 
 
 
6-Fluoro-N-[(1-hydroxycyclohexyl)methyl]-4-oxo-chromene-2-carboxamide (4). 
 
To a solution of 6-fluoro-4-oxo-chromene-2-carboxylic acid (0.5 g, 2.40 mmol) in DCM (10 ml) was 
added 2-chloro-4,6-dimethoxy-1,3,5-triazine (0.50 g, 2.88 mmol) followed by 4-methylmorpholine 
(0.97 g, 9.61 mmol) and the mixture stirred for 30 min. 1-(aminomethyl)cyclohexanol hydrochloride 
(0.60 g, 3.60 mmol) was then added in one portion and the mixture stirred at room temperature 
overnight. The mixture was then washed with NaHCO3 saturated aqueous solution (5 ml). Organic 
phase was evaporated to dryness and the residue was purified by SCX column (2 g) and product was 
eluted with MeOH. Methanol filtrate concentrated under reduced pressure. Product was purified by 
preparative HPLC eluting with a solution 0.1% HCO2H in water and acetonitrile. Fractions containing 
product were pooled together to obtain 6-fluoro-N-[(1-hydroxycyclohexyl)methyl]-4-oxo-chromene-
2-carboxamide (215 mg, 27% yield) as a white solid. ¹H NMR (500 MHz, CDCl3) δ 7.83 (dd, J=3.1, 7.9 
Hz, 1H), 7.60 - 7.56 (m, 1H), 7.46 (ddd, J=3.1, 7.5, 9.2 Hz, 1H), 7.37 (t, J=5.5 Hz, 1H), 7.16 (s, 1H), 3.54 
(d, J=6.1 Hz, 2H), 2.22 - 2.15 (m, 1H), 1.66 - 1.53 (m, 9H), 1.41 - 1.34 (m, 1H) ppm. 13C NMR (500 MHz, 
d6-DMSO) δ 177.21, 177.19, 160.68, 159.70, 158.73, 156.56, 152.05, 152.04, 125.37, 125.31, 123.64, 
123.44, 122.27, 122.20, 110.31, 110.14, 109.95, 70.81, 49.95, 35.45, 25.89, 21.93 ppm. LC-MS (ESI) 
m/z 320 (M+H)+. HRMS (ES+) calculated for C17H19FNO4 [M+H]+= 320.1293, observed for C17H19FNO4 
[M+H]+= 320.1290. 
 
N-[(4,4-difluoro-1-hydroxy-cyclohexyl)methyl]-6-fluoro-4-oxo-chromene-2-carboxamide (5).  
 
To a solution of 6-fluoro-4-oxo-chromene-2-carboxylic acid (0.40 g, 1.92 mmol) in DCM (20 ml) was 
added 2-chloro-4,6-dimethoxy-1,3,5-triazine (0.40 g, 2.3 mmol) followed by 4-methylmorpholine 
(0.78 g,7.69 mmol) and the mixture stirred for 30 min. 1-(Aminomethyl)-4,4-difluoro-cyclohexanol 
hydrochloride (0.53 g, 2.65 mmol) was then added in one portion and the mixture stirred at room 
temperature overnight. The mixture was then washed with NaHCO3 saturated aqueous solution (5 
ml). Organic phase was evaporated to dryness and the residue was purified by SCX column (10 g) and 
product was eluted with MeOH. Methanol filtrate concentrated under reduced pressure. Product 
was purified by preparative HPLC eluting with a solution of 0.1% HCO2H in water and acetonitrile. 
Fractions containing product were pooled together to obtain N-[(4,4-difluoro-1-hydroxy-
cyclohexyl)methyl]-6-fluoro-4-oxo-chromene-2-carboxamide (0.39 mg, 56 % yield) as a white solid. 
¹H NMR (500 MHz, DMSO) δ 8.99 (t, J=6.2 Hz, 1H), 7.89 - 7.73 (m, 3H), 6.88 (s, 1H), 4.80 (s, 1H), 3.37 
(d, J=6.4 Hz, 2H), 2.10 - 1.86 (m, 4H), 1.68 - 1.53 (m, 4H) ppm. 13C NMR (500 MHz, DMSO) δ 159.90, 
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156.41, 125.32, 123.72, 123.52, 122.24, 110.38, 110.17, 109.99, 69.69, 49.45, 31.66, 31.59, 29.50 
ppm. LC-MS (ESI) m/z 356 (M+H)+. HRMS (ES+) calculated for C17H17F3NO4 [M+H]+= 356.1104, 
observed for C17H17F3NO4 [M+H]+= 356.1110. 
 
 
2. Biochemistry 
2.1 Protein expression and purification method for recombinant KRS (UW) 
Recombinant KRS enzymes were cloned and expressed as previously described (1). Briefly, PCR 
amplicons were generated from the following template sources and primers:  
 
P. falciparum 3D7 cDNA  
(GGGTCCTGGTTCGATGGAAGTGGATCCAAGATTATATTT 
and CTTGTTCGTGCTGTTTATTAATTTGCTGGTCGCATAGTGGGAA),  
 
C. parvum Iowa II cDNA (GGGTCCTGGTTCGATGCACTATACTGATAATAGGTACAA 
and CTTGTTCGTGCTGTTTATTAATTTCCGCTATGTTGGTTGCTATG),  
 
human pET28a-KRS construct (Medicinal Bioconvergence Research Center, Seoul, South Korea)  
(GGGTCCTGGTTCGATGGCGGCCGTGCAGGCGG 
 and CTTGTTCGTGCTGTTTATTAGACAGAAGTGCCAACTGTTGTGC).  
 
The P. falciparum KRS had 76 residues removed at the N-terminus and replaced with maltose binding 
protein (MBP) to improve solubility. The C. parvum KRS had 45 residues removed at the N-terminus. 
The human KRS was the full length, untruncated sequence. All amplicons were cloned into the 
pAVA0421 expression vector using the ligation independent cloning (LIC) method. Recombinant 
plasmids were transformed into Rosetta BL21(DE3) competent cells and plated on LB agar plates with 
ampicillin, carbenicillin, and chloramphenicol selection. Clones were expressed using previously 
reported autoinduction methods and scaled to 2-litre cultures in a LEX bioreactor for large scale 
protein purification. Cell pellets were harvested and lysed with CHAPS detergent buffer and 
centrifuged to remove cell debris. The expressed products included a 6x-HIS tag appended to the N-
termini for IMAC purification. Subsequent size exclusion chromatography was employed to further 
purify the recombinant proteins (2).  
 
2.2 Protein expression and purification method for recombinant PfKRS1 (Dundee) 
The gene coding for P. falciparum KRS1 80-583, codon optimized for expression in E.coli, obtained 
from Genscript, was inserted into a His MBP TEV pET15b vector using Nde1 and Xho1 restriction sites. 
The resulting expression construct was introduced into BL21 (DE3) competent cells for protein 
production. A 120 ml overnight culture was set up and grown at 37°C 200 rpm for 16 h and was used 
the next day to inoculate 12 litres of Autoinduction+AMP media. Cells were grown at 37°C for 4 h 
then 20°C for 20 h before harvesting by centrifugation at 3,500 g for 30 min and storage at -20°C. The 
resulting cell pellet was 65 g. Lysis buffer (200 ml, 25 mM TRIS/500 mM NaCl/20 mM Imidazole pH 
8.5/protease inhibitor tablets/DNAase) was added and the pellets defrosted at 25°C in a water bath 
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for approximately 20 min. The slurry was then passed through a Cell Disrupter (Constant Systems) 
set at 30 KPSI to lyse the cells. The sample was then centrifuged at 40,000g for 20 min. The 
supernatant was then filtered using syringe filters to 0.2 µm. The supernatant was loaded onto a 5 
ml HiTrap Ni HP column that had been equilibrated with Buffer A (25 mM TRIS/500 mM NaCl/20 mM 
Imidazole pH 8.5) at 5 ml/min using an AKTA Pure system. Once loaded the column was washed with 
10 column volumes of buffer A followed by 5% Buffer B (25 mM TRIS/500 mM NaCl/500 mM 
Imidazole pH 8.5) to wash off His-rich contaminating proteins. A linear gradient of 5-50% B was used 
to elute the protein. Approximately 130 mg of protein was present in the fractions containing the 
PfKRS1 protein. The sample was then passed through a 0.2 µm filter, before loading onto a XK50/60 
Superdex 200 column using an AKTA Pure system at 4°C at 3 ml/min. The eluted protein was buffer 
exchanged into KRS Buffer (50 mM TRIS/200 mM NaCl/ 10 µM 2-mercaptoethanol pH 8.0) and 
concentrated to 7.75 mg/ml. 
 
2.3 Protein expression and purification method for recombinant CpKRS (Dundee) 
The C. parvum KRS had 45 residues removed at the N-terminus. All amplicons were cloned into the 
pAVA0421 expression vector using the ligation independent cloning (LIC) method. Recombinant 
plasmids were transformed into Rosetta BL21(DE3) competent cells and plated on LB agar plates with 
ampicillin, carbenicillin, and chloramphenicol selection. Clones were expressed using previously 
reported autoinduction methods and scaled to 2-litre cultures in shake flasks. Cell pellets were 
harvested and lysed with 100 mM HEPES/150 mM NaCl/5% Glycerol/20 mM imidazole/0.5 mM TCEP 
pH 7.5/DNase/Complete inhibitor tablets) using a Cell Disrupter (Constant Systems) at 30 KPSI and 
centrifuged at 40,000g for 20 min remove cell debris. The supernatant was loaded onto a 5 ml HiTrap 
Ni HP column that had been equilibrated with Buffer A (100 mM HEPES/150 mM NaCl/5% 
Glycerol/20mM imidazole/0.5 mM TCEP pH 7.5) at 5 ml/min using an AKTA Pure system. Once loaded 
the column was washed with 10 column volumes of buffer A. A 5% step of Buffer B (100 mM 
HEPES/150mM NaCl/5% Glycerol/500 mM imidazole/0.5 mM TCEP pH 7.5) was then used to wash 
off His-rich contaminating proteins. A linear gradient of 5-50% B was used to elute the protein. 
Approximately 287 mg of protein was present in the fractions containing the CpKRS protein. The 
sample was then concentrated to approximately 30 ml, passed through a 0.2 µm filter, before loading 
onto a XK26/60 Superdex 200 column using an AKTA Pure system at 4°C at 2 ml/min 10 ml at a time. 
The eluted protein was pooled then frozen at -80°C. The concentration of the protein was 1.3 mg/ml. 
Sometimes the protein was cleaved with PreScission protease overnight, a second Ni column 
performed in flow through mode to removed uncleaved protein. GST beads were then added to 
remove the PreScission Protease. The protein was then gel filtered as descripted above. 
 
2.4 Protein expression and purification method for recombinant HsKRS (Dundee) 
The gene coding for human KRS, codon optimized for expression in E. coli, was obtained from 
Genscript and cloned into a His PP pET15b vector using Nde1 and Xho1 restriction sites. The resulting 
vector was used to transform BL21 (DE3) competent cells for protein expression. A 120 ml overnight 
culture was set up and grown at 37°C 200 rpm for 16 h and used the next day to inoculate 6 litres of 
Autoinduction+AMP medium. This culture was grown at 37°C for 4 h then 20°C for 20 h. The cells 
were harvested by centrifugation at 3,500 g for 30 min then stored at -20°C. The resulting cell pellet 
was 50 g. Lysis buffer (150 ml, 25 mM HEPES/500 mM NaCl/20 mM imidazole/ 2mM DTT/10% 
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glycerol pH 7.5/protease inhibitor tablets/DNAase) was added and the pellets for defrosted at room 
temperature for approximately 10 min. The slurry was then passed through a Cell Disrupter (Constant 
Systems) set at 30 KPSI to lyse the cells. The sample was then centrifuged at 40,000g for 20 min. The 
supernatant was then filtered using syringe filters to 0.45 µm. The supernatant was loaded onto a 5 
ml HiTrap Ni HP column that had been equilibrated with Buffer A (25 mM HEPES/500 mM NaCl/20 
mM Imidazole/2 mM DTT/10% Glycerol pH 7.5) at 5 ml/min using an AKTA Pure system. Once loaded 
the column was washed with 10 column volumes buffer A. A 5% step of Buffer B (25 mM HEPES/500 
mM NaCl/500 mM Imidazole/2mM DTT/10% Glycerol pH 7.5) was then used to wash off His rich 
contaminating proteins. A gradient of 5-50% B was used to elute the protein. Approximately 55 mg 
of protein was present in the fractions containing the HsKRS protein. The sample was then passed 
through a 0.2 µm filter, before loading onto a XK26/60 Superdex 200 column equilibrated with Buffer 
C (25 mM HEPES/150 mM NaCl /2mM DTT/10% glycerol pH 7.0) using an AKTA Pure system at 4°C at 
2 ml/min. The sample was then dialyzed into 25 mM HEPES/500 mM NaCl/2 mM DTT/10% 
glycerol/0.25% azide pH 7.0. The protein was concentrated to 1 mg/ml and frozen at -80°C. 
Approximately 23 mg of protein was produced. 
 
2.5 PfKRS1, CpKRS and HsKRS Pyrophosphate Generation EnzChekTM Kinetic Measurements 
Steady-state kinetic measurements were conducted at room temperature using a PheraStar plate 
reader (BMG). End-points for the aminoacylation reaction of PfKRS1, which produces inorganic 
pyrophosphate that is converted to two molecules of inorganic phosphate using a pyrophosphatase 
enzyme, were measured using the EnzChek™ Phosphate Assay Kit, which gives an absorbance read-
out at 360 nm. Typical end-point assays were carried out in clear, flat-bottom, polystyrene, 384-well 
plates (Greiner) in an 80 µl reaction volume containing 100 mM Hepes, pH7.4; 100 mM NaCl; 20 mM 
MgCl2; 1 mM DTT; 0.05% IGEPAL®; 0.5 U/ml pyrophosphatase; 0.1 mM MESG; 0.5 U/ml PNP; 0.5 mM 
ATP; 5 mM L-lysine and 100, 300 or 400 nM recombinant PfKRS1, CpKRS or HsKRS respectively. Assays 
were performed by adding 40 µl of a 2-times concentrated reaction mixture containing all 
components with the exception of the substrates to all wells, and the reactions started by adding 40 
µl of a 2-times concentrated substrate mixture. The reaction was carried out for 6 h (PfKRS1 and 
CpKRS) or 12 h (HsKRS) at room temperature and then the absorbance of each well was read at 360 
nm. The substrates Km values were determined by varying the concentration of one of the substrates 
at saturating concentration of the other. Due to limiting assay conditions, i.e. low enzyme activity 
and high affinity substrates, for HsKRS, only apparent Km values could be obtained.  
 
Steady-state data were fitted using the nonlinear, least-squares, curve-fitting programs of Sigma-Plot 
for Windows, version 12.5. Individual saturation curves were fit to eq. 1 
 ! = #$$%& (1) 
 
where V is the maximal velocity (here expressed as µM/min of phosphate production), S is the 
substrate concentration and K is the Michaelis constant for the substrate (Km). Individual saturation 
curves displaying cooperativity were fit to eq. 2 
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! = #$'$'%&' (2) 
 
where n is the Hill slope.  
 
 
 
Figure S1. Steady-state kinetics of Pf, Cp and HsKRS (EnzChek).  
PfKRS1 saturation curves for (A) ATP and (B) L-lysine, CpKRS saturation curves for (C) ATP and (D) L-
lysine, and HsKRS saturation curves for (E) ATP and (F) L-lysine. Points are data and error bars indicate 
the standard deviation, n = 3. Lines are the best fit to eq. 1 (A, E and F) and eq. 2 (B, C and D). 
 
Table S1. Steady-state kinetic parameters for Pf, Cp and HsKRS (EnzChek). 
 
Enzyme Parameter Best fit Equation 
PfKRS1 Km,ATP (µM) 68 ± 3 1 
 Km,L-Lys (µM) 413 ± 37 2 
 Hill,L-Lys 0.89 ± 0.04 2 
CpKRS Km,ATP (µM) 346 ± 128 2 
 Hill,ATP 0.71 ± 0.09 2 
 Km,L-Lys (µM) 1045 ± 640 2 
 Hill,L-Lys 0.49 ± 0.06 2 
HsKRS Kmapp,ATP (µM) 2.22 ± 0.44 1 
 Kmapp,L-Lys (µM) 1.92 ± 0.37 1 
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2.6 PfKRS1 Hit Discovery Using Luciferase ATP Consumption (Kinase Glo®) (UW) 
An initial PfKRS1 high-throughput screen of the ‘TCAMS set’, a library of ~13,000 compounds which 
show phenotypic activity against P. falciparum (provided by GlaxoSmithKline) (3), was performed 
using the Kinase-Glo® assay platform (Promega, Madison, WI) . Assays were performed in 384-well 
format in buffer (as described in Table S3), 60 µM lysine, and 75 nM PfKRS1. Compounds were initially 
screened at single point concentrations of 7.5 µM and hits were repeated three times. Plates were 
incubated for 180 mins at 37°C after addition of compounds. Reactions were terminated by the 
addition of Kinase-Glo® reagent and read on an EnVision plate reader (PerkinElmer, Waltham, MA). 
Compound 2 was identified as a top hit with 71-91% inhibition.  
 
2.7 PfKRS1, CpKRS and HsKRS SAR Assay Using Luciferase ATP Consumption (Kinase Glo®) 
Inhibition of KRS activity by cladosporin and other compounds was assayed in the buffered medium. 
Assays were run in 96-well white flat-bottom polystyrene NBS™ Microplates (Corning Inc., Corning, 
NY) in a final reaction volume of 50 µl. Each assay well was composed of buffer (as described in Table 
S3), 10 µM lysine and either 8.1 nM PfKRS1, 8.1 nM CpKRS or 6.6 nM HsKRS. Enzymes were pre-
incubated with compound before the remaining assay reagents were added. The reaction was 
initiated by the addition of 2 µM ATP. The plate was incubated with shaking at 90 rpm and 30°C for 
120 min. Reactions were terminated by the addition of 50 μl Kinase-Glo® reagent (Promega, Madison, 
WI). Maximum and minimum signal controls were included in each reaction plate. The reaction was 
read on a MicroBeta2® plate reader (PerkinElmer, Waltham, MA). Assays were performed 
independently three times. Analysis and calculation of inhibitors IC50 values were performed using 
Graphpad® Prism software (GraphPad Software, San Diego, CA). 
 
2.8 PfKRS1 Mode of Inhibition Studies by Compound 5 Using Pyrophosphate Generation 
(EnzChek™) 
Using the EnzChek assay platform the IC50 value for compound 5 was determined at saturating 
concentrations of both substrates, 0.5 mM ATP and 5 mM L-lysine, in a series of 10 half-log dilutions 
of compound 5. To determine the steady-state inhibition parameters and patterns associated with 
compound 5, PfKRS1 activity was studied in the presence of variable concentrations of one substrate, 
ATP or L-lysine, fixed saturating concentration of the co-substrate (L-lysine or ATP) and several fixed 
concentrations of compound 5. Assay ready plates containing different concentrations of compound 
5 were prepared using an Echo® 550 acoustic dispenser (Labcyte Inc.). The assays were carried out 
as described above in section 2.5. 
 
Inhibition data obtained under saturating concentrations of substrates, and variable concentration 
of compound 5 were fit to eq. 3 
 ( = ()*+ + -./01-.2'3%456785 9'  (3) 
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Where ymin corresponds to no inhibition and ymax to maximum inhibition, IC50 is the concentration of 
inhibitor necessary to give 50% inhibition and I is the inhibitor concentration. Inhibition data showing 
linear competitive patterns in double-reciprocal plots were fit to eq. 4 
 ! = #&$:3% 5;2<%&  (4) 
 
where Ki is the dissociation constant for the enzyme-inhibitor complex. Inhibition data showing 
linear, uncompetitive patterns in double-reciprocal plots were fit to eq. 5 
 ! = #&$%&:3% 5;2<  (5) 
 
 
Table S2. Steady-state kinetic parameters for PfKRS1. 
 
Parameter Best fit Equation 
IC50 (µM) 0.210 ± 0.012 3 
Ki,ATP (µM) 0.032 ± 0.004 4 
Ki,L-lys (µM) 0.212 ± 0.014 5 
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Figure S2. Steady-state kinetics of PfKRS1 inhibition by compound 5.  
(A) Saturation curve for (A) Compound 5. Points are data and error bars indicate the standard 
deviation, n = 3. The line is the best fit to eq. 3. (B) Double-reciprocal plot illustrating the linear 
competitive inhibition pattern obtained when varying the concentration of compound 5 at fixed 
variable concentrations of ATP and saturating concentrations of L-lysine. Points are data obtained 
with 0 (black circles), 15 (red circles), 30 (green circles), 45 (yellow circles) and 60 nM (blue circles) of 
compound 5. The error bars indicate the standard deviation, n = 3. Lines are the best fit of the entire 
data set to eq. 4. The bottom figure is a replot of the slopes of the linear regression of the data at 
each concentration of compound 5, showing the linear dependence on inhibitor concentration. 
Points are data, and the line is the linear regression of the data. (C) Double-reciprocal plot illustrating 
the linear uncompetitive inhibition pattern obtained when varying the concentration of compound 5 
at fixed variable concentrations of L-lysine and saturating concentrations of ATP. Points are data 
obtained with 0 (black circles), 80 (dark blue circles), 160 (violet circles), 240 (pink circles) and 320 
nM (orange circles) of compound 5. The error bars indicate the standard deviation, n = 3. Lines are 
the best fit of the entire data set to eq. 5. The bottom figure is a replot of the intercepts of the linear 
regression of the data at each concentration of compound 5, showing the linear dependence on 
inhibitor concentration. Points are data, and the line is the linear regression of the data. 
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2.9 Recombinant KRS thermal shift assays (UW) 
Recombinant PfKRS1, CpKRS, and HsKRS were diluted to 4 µM in assay buffer containing 20 mM Tris-
HCl pH 8, 200 mM NaCl, 5 mM DTT, 5 mM MgCl2 and ligands (1 mM lysine; 40 µM ATP; and 40 µM 
inhibitors) in various combinations. Aliquots (10 µl) were added to a 96-well PCR plate and incubated 
at ambient temperature for 15 min. SYPRO® Orange dye (Invitrogen) was diluted in assay buffer to a 
5x concentration and 10 µl was added to the PCR plate to bring the final assay volume to 20 µl. The 
plate was sealed and pulse centrifuged to consolidate the assay mixture and remove air bubbles. 
Using a StepOne Plus RT-PCR thermal cycler (Applied Biosystems) to monitor fluorescence at an 
excitation/emission wavelength of 300/470-570 nm, the samples were heated from 25°C to 99°C at 
a ramp rate of .016°C/sec. Graphpad® Prism software (GraphPad Software, San Diego, CA) was used 
to determine melting temperatures (Tm) using Boltzmann sigmoidal analysis. 
 
Table S3. Thermal shift data for compounds with PfKRS1, CpKRS and HsKRS. 
 
 Compound Effects on LysRS Melting Temperature (∆Tm) 
Compound ID      1    2    5    3    4   
 Initial Tms (°C)                       
 
PfKRS CpKRS 
HsK
RS 
 PfK
RS 
CpK
RS 
HsK
RS 
 PfK
RS 
Cp
KRS 
HsK
RS 
 PfK
RS 
Cp
KRS 
HsK
RS 
 PfK
RS 
Cp
KRS 
HsK
RS 
 PfK
RS 
Cp
KRS 
HsK
RS 
 
 45.7 42.5 60.2  3.4 -0.1 -0.1  1.2 0.0 -0.3  1.3 -0.5 0.3  0.5 -0.2 -0.1  0.9 -0.2 -0.5  
ATP 45.9 42.1 59.9  3.5 0.1 0.3  0.9 0.7 0.3  0.9 -0.2 0.4  0.2 0.2 0.4  0.5 0.0 -0.1  
 Lysine 48.4 43.6 59.5  9.3 19.5 -9.2  7.4 19.3 
-
10.
0  7.5 14.7 -7.6  5.3 1.2 -8.4  7.5 18.4 -7.4  
ATP + 
Lysine 50.7 46.1 60.2  7.2 14.0 -8.2  5.1 11.7 -8.6  5.3 13.0 -7.4  2.4 0.8 
-
10.8  5.1 11.8 -7.2  
 
 
3. Cell Biology 
 
3.1 Assay methodology for Plasmodium falciparum (3D7) (Dundee).  
Cultures of the widely-used malaria reference strain of chloroquinine-sensitive Plasmodium 
falciparum strain 3D7 were maintained in a 5% suspension of human red blood cells cultured in RPMI 
1640 medium supplemented with 0.5% Albumax II (available from Gibco Life Technologies, San 
Diego, CA, cat.no. 11021-037), 12 mM sodium bicarbonate, 0.2 mM hypoxanthine, (pH 7.3), and 20 
mg/litre gentamicin at 37°C, in a humified atmosphere of 1% O2, 3% CO2 with a gas balance of 
nitrogen.  
Growth inhibition of the Plasmodium falciparum cultures was quantified in a 10-point dose response 
curve with a 1 in 3 dilution series from a top assay concentration of 50µM. This 384 well plate based 
fluorescence assay utilises the binding of SYBRgreen I (Thermo Fisher Scientific/Invitrogen cat.no. 
S7585) to double stranded DNA, which greatly increases the fluorescent signal at 528 nm after 
excitation at 485 nm. Mefloquine was used as a drug control to monitor the quality of the assay (Z’ = 
0.6 to 0.8, where Z’ is a measure of the discrimination between the positive and negative controls on 
a screen plate). Dose-response curves were determined from a minimum of 3 independent 
experiments. Compound bioactivity was expressed as EC50, the effective concentration of compound 
causing 50% parasite death. EC50 values were determined from a minimum of 3 independent 
experiments. 
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3.2 Cytotoxicity Studies (Dundee) 
In vitro cytotoxicity studies can be carried out using Hep G2 (Human Caucasian hepatocyte carcinoma, 
HPACC cat.no. 85011430) used as indicators for general mammalian cell toxicity. Hep G2 in vitro 
cytotoxicity can be assessed using the assay procedure as described (4).  
 
3.3 In vitro Cell Assay Data Analysis (Dundee) 
All data was processed using IDBS ActivityBase® raw data was converted into per cent inhibition 
through linear regression by setting the high inhibition control as 100% and the no inhibition control 
as 0%. Quality control criteria for passing plates were as follows: Z’> 0.5, S:B> 3, %CV(no inhibition control) 
< 15 . The formula used to calculate Z’ is  .  
All EC50 Curve fitting was undertaken using XLFit version 4.2 using Model 205 with the following 4 
parametric equation:  A + (?-A)(3%CD EF GH) ,where A=% inhibition at bottom, B=% inhibition at top, C= EC50, 
D= slope, x= inhibitor concentration and y= % inhibition. If curve did not reach 100% of inhibition, B 
was fixed to 100 only when at least 50% of inhibition was reached.  
 
3.4 Assay methodology for drug resistant Plasmodium falciparum (K1 and TM90C2B) 
(SwissTPH).  
Plasmodium falciparum drug-sensitive NF54 (airport strain from The Netherlands, provided by F. 
Hoffmann-La Roche Ltd) and resistant strains K1 and TM90C2B (from the Malaria Research and 
Reference Reagent Resource Center, accurate descriptions of the genetic backgrounds of these 
strains can be obtained at http://www.beiresources.org) were cultivated in a variation of the medium 
previously described (5, 6), consisting of RPMI 1640 supplemented with 0.5% ALBUMAX® II, 25 mM 
Hepes, 25 mM NaHCO3 (pH 7.3), 0.36 mM hypoxanthine, and 100 μg/ml neomycin. Human 
erythrocytes served as host cells. Cultures were maintained in an atmosphere of 3% O2, 4% CO2, and 
93% N2 in humidified modular chambers at 37 °C. Compounds were dissolved in DMSO (10 mM), 
diluted in hypoxanthine-free culture medium and titrated in duplicates over a 64-fold range in 96 
well plates. Infected erythrocytes (1.25% final hematocrit and 0.3% final parasitemia) were added 
into the wells. After 48 h incubation, 0.25 µCi of [3H]-hypoxanthine was added per well and plates 
were incubated for an additional 24 h. Parasites were harvested onto glass-fiber filters and 
radioactivity was counted using a Betaplate liquid scintillation counter (Wallac, Zurich). The results 
were recorded and expressed as a percentage of the untreated controls. Fifty percent inhibitory 
concentrations (EC50) were estimated by linear interpolation (7). 
 
3.5 In vitro parasite reduction ratio (PRR) assay with Plasmodium falciparum (GSK)  
The in vitro Parasite Rate Reduction assay (PRR) was conducted as previously described (8). Briefly, 
Plasmodium falciparum were exposed to compound 5 for 120 h at a concentration corresponding to 
10 x EC50. Drug was renewed daily over the entire treatment period. Samples of parasites were taken 
from the treated culture at intervals (24, 48, 72, 96 and 120 h time points), drug was washed out and 
)__(
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drug-free parasites were cultured in 96-well plates by adding fresh erythrocytes and new culture 
media. The number of viable parasites was determined by the serial dilution technique. Four 
independent serial dilutions were done with each sample to correct for experimental variation. 
 
 
Figure S3. The rate of kill of P. falciparum by compound 5. Data for standard drugs are provided for 
comparison as previously reported (8). 
 
3.6 Inhibition of Nanoluciferase expressing C. parvum growth in HCT-8 cells. (UW) 
Inhibition of C. parvum growth and EC50 determinations were performed with a Nanoluciferase-
expressing C. parvum parasite in HCT-8 cells. Oocysts were propagated in calves (Cryptosporidium 
Production Laboratory, School of Animal and Comparative Biomedical Sciences, University of 
Arizona) and isolated from stools by sucrose suspension and cesium chloride gradient. HCT-8 cells 
were seeded to a 384-well plate and allowed to grow for 72 h to reach 90-100% confluence at 37oC 
in 5% CO2. Oocysts were activated by 10-15 min incubation in 10% bleach (0.6% sodium hypochlorite) 
at room temperature and then washed with DPBS. 2000 oocysts per well were applied to 384-well 
plates with RPMI-1640 medium supplemented with 10% horse serum and 1% penicillin/streptomycin 
at the same time as compound addition. The compound and the oocysts were left in place for the full 
72 h growth time. The amount of luciferase-induced light emission was determined by lysing the cell 
monolayer, adding Nano-Glo® luciferase reagent (Promega, Madison, WI, USA), and reading on an 
EnVision Multilabel Plate Reader (Perkin Elmer, Waltham, MA, USA). Controls included infected wells 
with no addition of inhibitors and the background was taken as wells where no C. parvum was added. 
The percentage of growth versus infected cells with no inhibitor was calculated for each 
concentration of BKI and the half maximal effective concentration (EC50) values were determined by 
a sigmoidal dose response with variable slope using GraphPad Prism version 6.07 (GraphPad 
Software, La Jolla, California, USA).  
 
3.7 Assay method for measurement of in vitro inhibition of Cryptosporidium. (Vermont) 
The in vitro measurement of EC50, the effective concentration of compound causing 50% parasite 
death, versus Cryptosporidium were run in accordance with the method of Bessoff et.al. (9) Human 
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ileocecal adenocarcinoma (HCT-8) cells (ATCC) were cultured in RPMI 1640 medium (Invitrogen) 
supplemented with 10% fetal bovine serum (Sigma-Aldrich), 120 U/ml penicillin, and 120 µg/ml 
streptomycin (ATCC), and used between passages 9 and 39 for all experiments. Cryptosporidium 
parvum Iowa isolate oocysts were purchased from Bunch Grass Farm (Deary, ID). Oocysts were 
triggered to excyst by treating with 10 mM hydrochloric acid (10 min, 37°C) and then 2 mM sodium 
taurocholate (Sigma-Aldrich) in PBS (10 min, 16°C). They were then added to >95% confluent HCT-8 
cell monolayers in 384-well plates (~5,500 oocysts/well). Experimental compounds were added 3 h 
after infection, and assay plates were incubated for 48 h post-infection at 37°C under 5% CO2. Assay 
plates were then washed three times with PBS containing 111 mM D-galactose, fixed with 4% 
paraformaldehyde in PBS, treated for 10 min at 37°C with 0.25% Triton X-100, and stained with 1.33 
µg/ml of fluorescein-labeled Vicia villosa lectin (Vector Laboratories) and Hoechst 33258 (AnaSpec) 
at a final concentration of 0.09 mM. Epifluorescent images were acquired using a Nikon Eclipse 
TE2000 microscope with an automated stage programmed to focus on the center of each well and 
acquire a 3-by-3 composite image using an Exi Blue camera (QImaging, Canada) and a 20× objective 
(numerical aperture, 0.45). Nucleus and parasite images were exported separately as .tif files, and 
parasites and host cells were enumerated using macros developed for NIH ImageJ. Curves were 
plotted and the half-maximal effective (EC50) and 90% effective concentration (EC90) were calculated 
using GraphPad Prism software, version 6.01. 
 
3.8 In vitro Cryptosporidium time-kill curve assay (Vermont) 
Cryptosporidium parvum elimination during culture in HCT-8 cells was measured as recently 
described (10). Excysted C. parvum oocysts were added to HCT-8 cells in 384-well plates. Compounds 
were added 24 h after infection at 1, 3, 6, 9, and 12× the EC90, followed by incubation for an additional 
0, 6, 12, 24, 48, or 72 h before preparation, staining, and measurement of parasite and host cell 
numbers by epifluorescence microscopy. GraphPad Prism software was used to fit parasite decay 
curves to the number of parasites expressed as the percentage of parasites in vehicle-treated (DMSO) 
wells. 
 
A        B 
 
Figure S4. The rate of kill of C. parvum by cladosporin (A) and compound 5 (B). 
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3.9 Plasmodium vivax liver schizonts/ hypnozoites (University of Georgia) 
This is based on methods previously reported (11) 
 
3.10 Plasmodium berghei liver schizonts (UCSD) 
This is based on methods previously reported (12). In brief, HepG2-A16-CD81EGFP cells were 
cultured at 37 °C in 5% CO2 in DMEM media. For both P. berghei-Luc and HepG2 cytotoxicity assays, 
3x10**3 of the HepG2-A16-CD81EGFP20 cells in 5 µl of assay medium (DMEM without Phenol Red 
(Life Technologies, CA), 5% FBS, and 5x Pen Strep Glutamine (Life Technologies, CA)) at concentration 
6x10**5 cells/ml were seeded in white solid bottom 1536-well plates (custom GNF mold ref# 
789173-F, Greiner Bio-One), 20-26 h prior to sporozoites infection. For IC50 determinations, 18 h 
prior to infection 50 nl of compounds in 1:3 serial dilutions in DMSO (0.5% final DMSO concentration 
per well) were transferred with an Acoustic Transfer System (ATS) (Biosero) to the cells. Atovaquone 
(5µM) and puromycin (10 µM) at a single concentration were used as positive controls for 
the Pbluc and HepG2tox, respectively. 0.5% DMSO was used as negative control for both assays. Pb-
Luc sporozoites were freshly dissected from the infected A. stephensi salivary glands, filtered twice 
through a 20 µm nylon net filter (Steriflip, Millipore), counted in a hemocytometer, and adjusted to 
final concentration of 200 sporozoites per 1 µl in the assay media (DMEM without Phenol Red (Life 
Technologies, CA), 5% FBS, and 5x Pen Strep Glutamine (Life Technologies, CA). To infect the HepG2-
A16-CD81EGFP cells, 1x10**3 sporozoites per well (5 µl) were added with a single tip Bottle Valve 
liquid handler (GNF), and the plates were spun down at 37 °C for 3 min with a centrifugal force of 330 
x g on normal acceleration and brake setting (Eppendorf 5810 R centrifuge). The HepG2-A16-
CD81EGFP cell designated for toxicity studies were left uninfected, with 5 µl of additional assay media 
was added to each well to maintain equal concentrations of compounds with Pb-Luc 
infected plates. The plates were then incubated at 37 °C for 48 h in 5% CO2 with high humidity to 
minimize media evaporation and edge effects. 
 
After incubation at 37 °C for 48 h, the EEF growth and HepG2-A16-CD81EGFP cell viability were 
assessed by a bioluminescence measurement as follows: Media was removed by spinning the 
inverted plates at 150 x g for 30 s; 2 µl per well of BrightGlo (Promega) for quantification of Pb-Luc 
EEFs or CellTiterGlo (Promega) reagent (diluted 1:2 with deionized water) for quantification of 
HepG2-A16-CD81EGFP cell viability were dispensed with the MicroFlo (BioTek) liquid 
handler. Immediately after addition of the luminescence reagent, the luminescence was measured 
by the Envision Multilabel Reader (PerkinElmer). 
 
3.11 Plasmodium falciparum stage V gametocytes (UCSD) 
This is a modification of the previously reported method (13). Asexual P. falciparum parasites (NF54) 
from a clone G3 were grown at 5% hematocrit in O+ human erythrocytes in serum-containing 
complete media (RPMI 1640, gentamicin 0.05 mg/ml, hypoxanthine 0.05 mg/ml, HEPES 38.4 mM, 
sodium bicarbonate 0.2% [w/v], D-glucose 0.2% [w/v], sodium hydroxide 3.4 mM, 11.9% [w/v] heat-
inactivated human serum [O+] and at 37 °C under low-oxygen conditions (3% O2, 5% CO2, and 92% 
N2) and a parasitemia between 0.5% and 3%. Ring-stage parasites were synchronized at 3% 
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parasitaemia (d-6) with 5% (w/v) D-Sorbitol. On day −4, 45ml of complete media was added to the 
culture flask to stress via hematocrit drop now at 2.5%. The on d-3 and d-2 only 45 ml of the media 
was substituted for fresh media. On d-1 a complete media change was performed and the 
hemocrit restored to 5%.  All gametocytes were treated with 50 mM NAG on days 0–9. 
 
Gametocyte stage V parasites were diluted to 0.5%–0.75% gametocytemia and 1.25% hematocrit 
into serum-free SALSSA screening media (RPMI 1640, gentamicin 0.05 mg/ml, hypoxanthine 0.014 
mg/ml, HEPES 38.4 mM, sodium bicarbonate 0.2% [w/v], D-glucose 0.2% [w/v], sodium hydroxide 
3.4mM and 0.4% [w/v] AlbuMAX II). Cultures were dispensed (40 µl versus 10 μl) into 384 well plates 
containing 50 nl or 2.5 nl of compound (final concentration of 1.25 to 12.5 µM) using a MultiFlo 
dispenser. Plates were incubated at 37°C for 72 h under low-oxygen conditions. For SaLSSA 10 µl (384 
well) of 2.5 µM MitoTracker Red CMXRos and 0.13% saponin solution (w/v) in screening media was 
added to each well, and plates were incubated for 180 min at 37 °C.  
 
Imaging of 384-well plates was performed using a high content imaging system (Operetta, Perkin 
Elmer) and Harmony software for image analysis. Viability indices were calculated by dividing the 
particle count of each compound-treated well by the average particle count of the DMSO wells per 
plate and range from 0 (active compound) to >1 (inactive). Z values were calculated using DMSO-
treated gametocytes as positive and uninfected red blood cells as negative wells. 
 
3.12 Plasmodium falciparum gamete formation (Imperial) 
This is based on methods previously reported (14). Mature P. falciparum stage V gametocytes (NF54) 
were incubated with test compound for 24 h at 37°C in 384-well plates containing complete culture 
medium (RPMI 1640, 25 mM HEPES, 2 g/l D-glucose, 2 g/l sodium bicarbonate, 50 mg/l 
hypoxanthine, 10% human serum) under a low oxygen environment (3% O2/5% CO2/92% N2). 
Gametogenesis was triggered by dispensing 10 µl ookinete medium (RPMI 1640, 25 mM HEPES, 2 g/l 
D-glucose, 2 g/l sodium bicarbonate, 50 mg/l hypoxanthine, 100 µM xanthurenic acid) also 
containing 2.7 µg/ml anti-Pfs25-Cy3 into each well and cooling the plate on a metal block at 4 °C for 
4 min. Fifteen s later male gametogenesis was recorded by brightfield imaging using times 6 objective 
and then the plate stored at 26 °C for a further 24 h to allow female gametes to develop. Female 
gamete formation was assessed by fluorescence microscopy using x6 objective to identify anti-Pfs25-
positive cells. Male and female gamete formation was quantified with respect to DMSO and 20 µM 
gentian violet negative and positive controls. 
 
3.13 Activity against Cryptosporidium hominis (CALIBR) 
This is based on methods previously reported (10).  
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4. DMPK (Dundee) 
 
4.1 Aqueous solubility 
The aqueous solubility of the test compounds was measured using laser nephelometry, as described 
previously (15). Compounds were subject to serial dilution from 10 mM to 0.47 mM in DMSO. An 
aliquot was then mixed with MilliQ water to obtain an aqueous dilution plate with a final 
concentration range of 250 - 13 µM, with a final DMSO concentration of 2.5 % (v/v). Triplicate 
aliquots were transferred to a flat bottomed polystyrene plate which was immediately read on the 
NEPHELOstar (BMG Lab Technologies). The amount of laser scatter caused by insoluble particulates 
(relative nephelometry units, RNU) was plotted against compound concentration using a segmental 
regression fit, with the point of inflection being quoted as the compounds aqueous solubility (µM).  
 
4.2 FaSSIF solubility 
Drug dissolution in biorelevant media which simulates the liquid environment within the upper 
gastro-intestinal tract has been shown to have a significant impact on the absorption rate of drugs 
into the blood stream and is more a more accurate determination of oral dose solubility than simple 
aqueous solubility performed at neutral pH and without any associated bile acids and fats. This 
method is based on that of Fagerberg et al. (16) where the FaSSIF has pH 6.5 and contains 3 mM 
sodium taurocholate and 0.75 mM lectithin. FaSSIF blank only has pH 6.5 and is devoid of salts and 
fat components. 
 
Briefly, approximately 3 mg of test compound is accurately weighed in duplicate and 1 ml of FaSSIF 
blank or FaSSIF is added to this before vortexing to mix and then incubating in a shaking environment 
at 1300 rpm at 37 °C for 5 h. The sample is then centrifuged at 10,000 rpm for 3 min before the 
supernatant is subject to HPLC analysis at 254 nm UV detection wavelength. Typically, 10 µl 
supernatant injections are sufficient to achieve peak areas which fall within the 6 point standard 
curve of analyte concentrations injected onto the column, although this may be increased up to 40 
µl for more insoluble compounds where necessary. 
 
The amount of drug in the supernatant is interpolated from a 6 point standard curve for the drug 
prepared over the range 0.05 – 2.5 µg injected onto the column. The HPLC method uses a Luna C18 
column (Phenomenex, Macclesfield, UK, 4.6 x 150 mm) with 5 µm particle size. Mobile phase A (MPA) 
is deionised water containing 0.1% (v/v) formic acid and mobile Phase B (MPB) is MeCN containing 
0.1% (v/v) formic acid. The LC system used was a Dionex Ultimate 3000 HLPC where 95% MPA was 
held for the initial 30 s of the run, then a linear gradient to 5% MPA takes place over the next 4 min 
before being held at 5% MPA for a further 3.2 min before re-equilibration back to 95% MPA at 9 min. 
Flow rate was 1 ml/min. 
 
Positive control drugs (cinnarizine and warfarin) are included in every experimental run, to give low 
and high solubility results for QC purposes. 
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4.3 CHI logD 
Lipophilicity is a key descriptor of the ability of a drug to partition between aqueous and lipid 
environments within a cell membrane/tissue and hence how easily it could interact with intracellular 
targets. This can be determined by either log D or Log P measurements, which are traditionally quite 
time consuming and require quite large amounts of compound to determine accurately.  
 
The CHI Log D assay, first described by by Valkό et al. (17), has been adapted and performed at pH 
7.4 herein and utilises a 5 µl aliquot from a 10 mM DMSO stock which is diluted to 250 µM by adding 
195 µl of MeCN:H2O (v/v) and mixing in a 96-well plate. An aliquot (10 µl) is then injected onto a Luna 
C18 column (Phenomenex, Macclesfield, UK, 4.6 x 150 mm) with 5 µm particle size. Mobile phase A 
(MPA) is 50 mM ammonium acetate (pH 7.4) and mobile Phase B (MPB) is MeCN. The LC system used 
was a Dionex Ultimate 3000 HLPC where 100% MPA was held for the initial 1.5 min of the run, then 
a linear gradient to 0% MPA takes place over the next 10 min before being held there for a further 
2.5 min before re-equilibration back to 100% MPA at 14 min with data collection continuing until 15 
min. Flow rate was 1 ml/min with detection at 254 nm UV and ambient temperature. 
 
The retention time (tR) of the unknown drug is interpolated from the slope and intercept created 
using retention times of standard mixture components containing paracetamol, theophylline, 
caffeine, benzimidazole, colchicine, carbamazepine, indole, propiophenone, butyrophenone, 
valerophenone and hepatophenone (prepared at 10 µg/ml in MeCN:water [1/1, by volume]), which 
covers the CHI log D range from -1 to 4.44 using the following equations; 
CHI = (retention time of unknown x slope of line through standard mixture tR) – intercept of the 
equation drawn through standard mixture tR 
CHI Log D = (0.0525 * CHI) -1.467 
 
4.4 Intrinsic Clearance (CLi) experiments 
The mouse and human cryopreserved hepatocytes were supplied by Xenotech (batches MC539 na 
HUE50H). The procedure was carried out as reported previously (15). Test compound (0.5 µM in 
DMSO) was incubated with female CD1 mouse, male Sprague-Dawley rat or pooled human mixed 
gender liver microsomes (Xenotech LLC TM ; final volume of 0.5 mg/ml in 50 mM potassium phosphate 
buffer, pH 7.4 containing 0.5% [v/v] DMSO) and the reaction initiated by the addition of excess 
NADPH (8 mg/ml prepared in 50 mM potassium phosphate buffer, pH 7.4). Immediately, at time zero, 
then at 3, 6, 9, 15 and 30 min an aliquot (50 μl) of the incubation mixture was removed and mixed 
with acetonitrile (100 μl) containing internal standard to stop the reaction. Internal standard was 
added to all samples, the samples centrifuged to sediment precipitated protein and the plates then 
sealed prior to UPLC-MS/MS analysis using a Quattro Premier XE (Waters Corporation, USA). XLfit 
software (IDBS, Guildford UK) was used to calculate the exponential decay and consequently the rate 
constant (ke-1) from the ratio of peak area of test compound to internal standard at each time point. 
The rate of intrinsic clearance (CLi) of each test compound was then calculated using the following 
calculation: 
 
CLi (ml/min/g liver) = ke-1 x V x Microsomal protein yield 
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where V (ml/mg protein) is the incubation volume/mg protein added (0.5) and microsomal protein 
yield is taken as being 52.5 mg protein per g liver. Verapamil (0.5 µM) was used as a positive control 
to confirm acceptable assay performance. Experiments were performed using a single time-course 
experiment. 
 
4.5 Hepatocyte stability 
Cryopreserved hepatocytes were used to take non-CYP mediated Phase I and Phase II enzymes into 
account in the determination: hence values for intrinsic clearance using whole cells tend to be higher 
than those determined using liver microsomes or other subcellular liver fractions and could be more 
predictive of a metabolic rate determined in vivo. 
 
Cryopreserved mouse (batch MC539) and human (batch HUE50H) hepatocytes were supplied by 
ThermoFisher Scientific, Paisley, UK and Xenotech, LLC, respectively.  Cryopreserved hepatocytes 
were rapidly thawed in a pre-heated water bath at 37 °C before adding to 50 ml of pre-warmed CHRM 
media (ThermoFisher Scientific, Paisley, UK) and mixed gently. Hepatocytes were then centrifuged at 
room temperature at 55 x g for 3 min or 100 x grcf  for 10 min for mouse and human respectively.  
before re-suspending in 1 ml Williams medium E (WME) supplemented containing media cocktail and 
dexamethasone both supplied by ThermoFisher Scientific)The supplemented WME was pre-warmed 
to 37 °C and had been bubbled through with CO2 for at least 30 minutes prior to use. Cell viability 
and density were determined by trypan blue exclusion (10% trypan blue, by volume) using a 
disposable haemocytometer before being diluted to a working cell density of 0.5 million viable 
cells/ml in supplemented WME. Only suspensions which achieved >80% post-thaw viability were 
used in experiments. 
 
Test compounds were supplied as 10 mM DMSO stock solutions and were diluted in supplemented 
WME in a two stage dilution to achieve a final stock concentration of 1 µM containing 1% DMSO (v/v). 
200 µl of these solutions were transferred to a clean 48-well non-collagen coated plate and pre-
warmed in a humidified 5% CO2 atmosphere incubator and subject to gentle mixing (~90 rpm) on a 
orbital rotating platform. The reactions were initiated by the addition of 200 µl of hepatocyte 
suspension and 20 µl sample was removed at 10 time points up to 120 min and terminated by 
precipitation in 80 µl MeCN (containing internal standard) in a 96 well polycarbonate analysis block. 
Hence samples were incubated at final substrate concentration of 0.5 µM containing 0.5% (v/v) 
DMSO and 0.25 million cells/ml. The solvent component was reduced to 50% (by volume) in 
terminated samples by adding 100 µL H2O:MeCN before the sample plate was centrifuged at 3570 
rpm for 10 min to pellet the cellular debris and the supernatants transferred to a clean 96 well plate 
prior to analysis using identical methods, equipment and data processing as for microsomal CLi 
determinations above except that a scaling factor of 120 million cells/g liver was applied to the rates 
of reaction to express the values as ml/min/g liver. 
 
Positive control incubations with 7-ethoxycourmarin, 7-hydroxycoumarin, verapamil and phthalazine 
were included in all experiments to confirm that cytochrome P450, Glucuronidation/sulfation, and 
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aldehyde oxidase pathways were active and were able to contribute to the metabolic rate, provided 
that the compounds tested were substrates for these enzymes. 
 
4.7 Fluorescence-based CYP Inhibition using recombinantly expressed CYP bactosomes 
Fluorogenic CYP inhibition studies were conducted at 37 °C in 96-well, flat-bottom, clear polystyrene 
plates. Incubation mixtures containing EasyCYP bactosomes (1000 pmol/ml, 10 mg/ml Cypex TM, 
Dundee, UK), fluorogenic substrate (Cypex TM) and 50 mM potassium phosphate buffer (pH 7.4) were 
prepared at the following final concentrations: CYP1A2, 5 pmol/ml + 35 µM ethoxyresorufin (ER); 
CYP2C9, 10 pmol/ml + 30 µM 7-methoxy-4-(trifluoromethyl)-coumarin (MFC); CYP2C19, 5 pmol/ml + 
25 µM 3-cyano-7-ethoxycoumarin (CEC); CYP2D6, 10 pmol/ml + 6 µM 7-methoxy-4-(aminomethyl)-
coumarin (MAMC); CYP3A4, 10 pmol/ml + 1 µM diethoxyfluorescein (DEF) and 10 pmol/ml + 15 µM 
7-benzyloxyquinoline (BQ).  Bactosome control protein was included in reactions to give a final 
concentration of 0.0125 (1A2 and 2C9 only) or 0.025 mg/ml (all other isoforms).  Test compounds 
were prepared as 0.5 mM solutions in DMSO and serially diluted 1 in 3.03, 1 in 3.3 alternatively in a 
v-bottomed 96 well plate to give a 7 point concentration range of 500 – 50 µM.  Positive control 
inhibitor, miconazole, was prepared as a 500 µM solution in DMSO and similarly diluted.  
 
For each isoform, 220 µl of incubation mix was added to each well of a 96-well, flat-bottom, clear 
polystyrene plate.  Aliquots (5 µl) of each compound 5 concentration was then mixed with 220 µl of 
the incubation mix and pre-incubated at 37 °C for 5 min (final test compound concentration range: 
10, 3.3, 1.0, 0.33, 0.1, 0.033, 0.01 and 0 µM; miconazole 10, 3.3, 1.0, 0.33, 0.1, 0.033, 0.01 and 0 µM) 
both containing final DMSO concentrations of 2% (v/v).  Reactions were initiated by the addition of 
25 µl regenerating cofactor solution (28 mM glucose-6-phosphate, 2.2 mM NADP, 6 U/ml glucose-6-
phosphate dehydrogenase (from Baker's yeast S. cerevisiae) in 2% w/v NaHCO3, Sigma) and 
subsequent production of fluorescence metabolite measured at 1 min intervals over a 10 min period 
using a BMG Optima fluorescence detector (ER: Exc 540nm, Em 590nm, MFC: Exc 430 nm, Em 540nm, 
CEC: Exc 405 nm, Em 450 nm, MAMC: Exc 405 nm, Em 450 nm, DEF: Exc 430 nm, Em 540 nm, 7BQ: 
Exc 485 nm, Em 520 nm). Reaction times were verified to be within the limits of kinetics linearity. 
 
Fluorescence responses were calculated as a percentage of uninhibited solvent matched control and 
plotted against compound concentration to provide IC50 values using the following equation using 
XLfit curve fitting software (IDBS) ensuring that the control values fell within 80-120% of mean 
replicate wells across the plate. 
 
4. 8 Human ether-à-go-go related gene (hERG) K+ assay (Outsourced) 
Compounds were tested for inhibition of the human ether-à-go-go-related gene (hERG) K+ channel 
using IonWorks patch clamp electrophysiology. Eight-point concentration-response curves were 
generated on 2 occasions using 3-fold serial dilutions from the maximum final assay concentration.  
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5. In vivo pharmacokinetic and efficacy studies 
 
5.1 In vivo pharmacokinetics (Dundee) 
Compound 5 was dosed as a bolus solution intravenously at 3mg free base/kg (dose volume: 5 ml/kg; 
dose vehicle: 10% DMSO, 40% PEG400 and 50% MilliQ water) to female Balb/c mice (n=3) or dosed 
orally by gavage as a solution at 10 mg free base/kg (dose volume: 10 ml/kg; Dose vehicle: 0.5% 
hydroxypropylmethylcellulose, 0.4% Tween 80 and 0.5 benzyl alcohol to female BALB/c mice 
(n=3/dose level). Blood samples (10 μl) were taken from each mouse at 5, 15 and 30 min, 1, 2, 4, 6, 
8 and 24 h post-dose, mixed with nine volumes of distilled water and stored frozen until UPLC-MS/MS 
analysis. The level of each compound in mouse blood was determined by UPLC-MS/MS as previously 
reported (18). Pharmacokinetic parameters were derived from the blood concentration time curve 
using PKsolutions software v 2.0 (Summit Research Services, USA). 
 
5.2 In vivo antimalarial efficacy studies in P. falciparum (SwissTPH) 
Compounds were tested in the murine P. falciparum SCID model essentially as described (19).  Briefly, 
compound 5, formulated in 0.5% hydroxypropylmethylcellulose (HPMC); 0.4% Tween 80; 0.5% 
benzoyl alcohol, was administered to a cohort of age-matched female immunodeficient NOD-scid IL-
2Rγnull mice (The Jackson Laboratory, Bar Harbor, ME) previously engrafted with human erythrocytes 
(generously provided by the Blood Bank in Zürich, Switzerland). The mice were intravenously infected 
with 2×107 P. falciparum Pf3D70087/N9-infected erythrocytes (day 0). On day 3 after infection, mice 
(n=2) were randomly allocated to treatments that were administered once a day for 4 consecutive 
days by oral gavage at 10 ml/kg. Parasitemia was measured by microscopy and flow cytometry using 
anti-murine erythrocyte TER119 monoclonal antibody (Pharmingen, San Diego, CA) in serial 2 μl 
blood samples taken every 24 h until assay completion. 
 
Serial samples of peripheral blood (25 μl) were taken from the mice of the efficacy experiment by tail 
puncture at 1, 2, 6 and 24 h after the first administration. The samples were immediately lysed by 
mixing with 25 μl of water, immediately frozen on dry ice and stored at -80°C until bioanalysis (carried 
out at GSK, Tres Cantos). The compounds were extracted from 10 μl of each lysate with 180 μl 
AcN:MeOH (80:20; v:v) and stored frozen at -80º C until analysis by LC/MS/MS in AB Sciex API4000 
(AB Sciex, Framingham, MA). The compound concentration versus time data were analyzed by non-
compartmental analysis (NCA) using PhoenixR Version 6.3 (Pharsight Corporation, Mountain View, 
CA, USA). Additional statistical analysis was performed with GraphPad PrismR (GraphPad Software 
Inc, San Diego CA, USA). 
 
5.3 In vivo antimalarial efficacy studies in P. falciparum (TAD) 
The efficacy of compound 5 against P. falciparum in vivo was evaluated in a non-myelodepleted 
humanized mouse model (20). Female immunodeficient NOD-scid IL-2Rγnull mice (NSG) (Charles 
River, France) of 25-28 gr bodyweight were housed in The Art of Discovery animal facility at BIC 
Bizkaia building (Derio, Basque Country, Spain), which is equipped with HEPA filtered in/out air-
conditioned with 15 air renovations per h at 22 ± 2 ºC; 40-70% relative humidity; 12 h light/dark 
period. The mice were accommodated in racks with ventilated disposable cages (Innovive) in groups 
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of up to five individuals with autoclaved dust-free corncob bedding (Innovive) and fed with g-
irradiated standard pellet (Envigo) and ultra-filtered water (Innovive) ad libitum. 
 
The mice of the study were engrafted by daily intraperitoneal injection of 1 ml of human erythrocytes 
(Basque Center of Transfusion and Human Tissues, Galdakao, Spain and Bank of Blood and Tissues, 
Barcelona, Spain) suspended in RPMI1640 medium, 25% (vol/vol) decomplemented human serum, 
3.1 mM hypoxanthine at 50%-75% hematocrit. The suspension was injected daily during the whole 
experiment. At a minimum of 40 % of chimerism (7-10 days after start of chimerization), the mice 
were infected by i.v. route with 35×106 Plasmodium falciparum Pf3D70087/N9-infected erythrocytes 
suspended in 0.3 ml of saline. The P. falciparum Pf3D70087/N9 strain (19) was kindly donated by Dr. 
Sergio Wittlin (Swiss Tropical and Public Health Institute, Basel, Switzerland). The inoculum was 
obtained from blood of CO2-euthanized donor mice harbouring 5-10% parasitemia. A single inoculum 
was used for all individuals of the efficacy study. 
 
The drug was daily formulated as a transparent solution in 0.5% hydroxypropylmethylcellulose, 0.4% 
Tween 80, 0.5% benzyl alcohol in ddH2O (HPMC). Drug treatment was administered once a day by 
oral gavage with 20G straight, reusable, feeding needles (Fine Science Tools GmbH) at 10 ml/kg for 
four consecutive days starting 72h after infection (~1% of patent parasitemia in peripheral blood). 
 
Serial 2 µl blood samples of peripheral blood from P. falciparum-infected mice were stained with TER-
119-Phycoerythrine (marker of murine erythrocytes) and SYTO-16 (nucleic acid dye) and then 
analyzed by flow cytometry (Attune NxT Acoustic Focusing Flow Cytometer, InvitroGen) as described 
(21). The limit of quantitation is set to 0.01% for a minimum of 100 infected events as statistically 
significant sample (~106 total erythrocytes counted). Parasitemia is expressed as the % of parasitized 
erythrocytes with respect the total erythrocytes in circulation and/or as the absolute concentration 
of circulating parasitized erythrocytes. A qualitative analysis of the effect of treatment on P. 
falciparum Pf3D70087/N9 was assessed by microscopic analysis of Giemsa-stained blood smears 
prepared with blood samples at 48 h and 96 h after drug treatment inception. 
 
The concentration of compound 5 in whole blood of the mice of the efficacy study was measured in 
25 μl samples of peripheral blood taken at 0.5, 1, 2, 4, 8, 23, 71, 74 and 95 h after the first dosing. 
The samples were mixed with 25 µl of H2O MilliQ, immediately frozen on dry ice and stored at -80 ºC 
until analysis. Blood from control P. falciparum-infected humanized mice was used for preparation 
of standard curves, calibration and quality control purposes. The compound was extracted from 10 
µl of lysates obtained by protein precipitation of diluted blood samples using standard liquid-liquid 
extraction methods. The samples were analyzed by LC-MS/MS for quantitation in a Waters UPLC-
TQD (Micromass, Manchester, UK). Blood concentration vs time was analyzed by non-compartmental 
analysis (NCA) using Phoenix WinNonlin vers.7.0 (Certara), from which exposure-related values (Cmax 
and AUC0-t) and tmax, were estimated. 
 
Efficacy is expressed as the effective dose in mg/kg and the corresponding average daily exposure 
that reduced parasitemia at day 5 of the assay by 90 % with respect to untreated mice (denoted as 
ED90 and AUCED90, respectively). These parameters are calculated by fitting the variables X= log10[dose 
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level in mg/kg] and X= log10[AUC of compound during the first 23 h after the first drug administration, 
in ng·h·ml-1], respectively, versus Y= log10[parasitemia at day 5 of the assay], where each individual of 
the study is defined as an ordered pair, to the function Y=Bottom + (Top-Bottom)/(1+10((LogED50-
X)*HillSlope)). 
 
Data analysis was performed using GraphPad Prism 7.0 (GraphPad Software), Excel 2016 (Microsoft) 
and R free software (https://www.r-project.org) for data plotting and statistical modelling. Phoenix 
WinNonlin vers.7.0 (Certara) was used for PK Non-Compartmental Analysis. 
 
5.4 Measurement of anti-Cryptosporidium in vivo efficacy in IFN-γ-knockout mice (Georgia) 
The Nluc-C. parvum IFN-γ-knockout (IFN-γ KO) mouse in vivo experiments were run in accordance 
with the published method (22). Briefly, female C57BL/6 IFN-γ KO mice, aged 6–8 weeks were 
infected with 10,000 C. parvum UGA1 Nluc (Vinayak et al 2015, Nature) transgenic oocysts. Mice (n=5 
per group) were administered 20 mg/kg of compound 5 formulated in 3% ethanol, 7% Tween 80, 90% 
saline or the formulation (vehicle) by oral gavage. Treatment with compound 5 (20 mg/kg) or vehicle 
was started at day 4 post infection and continued daily for 7 days (day 4 to day 10). Fecal samples 
from mice cage were collected (during and after treatment, till day 35), and luminescence assays 
were performed as described previously (22, 23). For the Nluc assay, 20 mg of mashed fecal material 
was suspended in 1 ml of lysis buffer (50mM TrisHCl pH7.6, 2mM DTT, 2mM EDTA, 10% glycerol, 1% 
triton-X 100) and 3 mm glass beads were added to the tube followed by vortexing for 1 min. The 
lysate was subjected to a brief spin in the centrifuge, and the supernatant (three aliquots of 100 μl 
each) were added to 96 well white plates. 100 µl of reconstituted NanoGlo buffer containing 1:50 of 
NanoGlo substrate (Promega) was added to each well, and luminescence was read on a Synergy H4 
Hybrid Microplate Reader (BioTek Instruments).  
 
5.5 Measurement of anti-Cryptosporidium in vivo efficacy in NOD SCID gamma mice (Vermont) 
The cryptosporidiosis NOD SCID gamma mouse model were run in accordance with the method 
published in R. S. Jumani et. al. (10). Three to four week old male NOD SCID gamma mice (NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ) were purchased from Jackson Laboratory (Bar Harbor, ME) and were housed 
for one week prior to infection with ~105 C. parvum Iowa isolate oocysts by oral gavage. Compounds 
were prepared for dosing by suspension in DMSO, sonication and freezing aliquots at -80 °C. On each 
day of treatment, aliquots of compound were thawed, mixed well by vortexing, diluted in 1% 
hydroxypropylmethylcellulose (HPMC) (5% DMSO in 100 µl 1% HPMC), sonicated, mixed thoroughly, 
and then administered by oral gavage. Oral treatment with experimental compounds, paromomycin 
(positive control), or the HPMC/DMSO vehicle alone was begun 7 days after infection, and continued 
for 7 days. Fecal oocyst shedding was quantified by qPCR just before starting treatment and one day 
after completion of treatment (10). 
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6. Modelling and Molecular Dynamics Simulations 
 
6.1 Initial models 
The crystal structure of PfKRS1 dimer in complex with compound 2 (PDB 6AGT) was used to construct 
all PfKRS1 models for molecular dynamics (MD) simulations: with a bound ligand (compound 5), in 
the presence and absence of lysine. A model of the human KRS in complex with compound 5 was 
obtained by superimposing the PfKRS1 structure with the available crystal structure of the human 
KRS in complex with cladosporin (PDB ID 4YCU) (24). Finally, the crystal structure of CpKRS with a 
bound compound 5 was simulated in the presence and absence of lysine. PfKRS1, CpKRS and HsKRS 
were also simulated in the apo state (no ligand but in the presence of lysine). A summary of models 
and MD simulations performed in this article is presented in Table S4 
 
6.2 System preparation.  
The systems for MD simulations were prepared with the utility LEaP, which is integrated in the suite 
of programs AMBER 16 (25). The ff14SB force field (26) was used. The N- and C-termini of the proteins 
were capped with an acetyl (ACE) and methylated amino group (NME), respectively. The geometries 
of the ligands were refined with Gaussian03 (27) at the HF/6-31G* level. The optimized geometries 
were used to calculate the electrostatic potential-derived (ESP) charges using the RESP methodology 
(28), as implemented in the Antechamber module in AMBER 16. The force field parameters for the 
ligand were generated with the Antechamber module, using the general AMBER force field (GAFF 
2.0). The force field parameters and partial charges for the isolated lysine were taken from a study 
by Horn (29). Each simulated system was immersed in a water box (TIP3P water model) and 
neutralized by adding the appropriate number of counterions. This was followed by steepest-descent 
energy minimization to remove steric clashes.  
 
6.3 MD simulation protocol.  
MD simulations were performed using the pmemd.cuda module of AMBER 16. The cut-off distance 
for the non-bonded interactions was set to 10 Å. The periodic boundary conditions were used. 
Electrostatic interactions were treated using the smooth particle mesh Ewald method (30). The 
SHAKE algorithm was applied to all bonds involving hydrogen atoms, and a time step of 2 fs was used 
throughout (31). Each energy minimized system was heated to 300K, equilibrated for 10 ns, and 
further simulated for 500 ns without any restraints.  
 
6.4 MD Analysis.  
Protein structures and MD trajectories were visually inspected and analyzed using the molecular 
visualization programs PyMOL (32) and VMD (33). Both copies of the dimer systems were used for 
analysis. Interatomic distances, angles and root-mean-square deviations (RMSD) with respect to a 
reference structure were monitored using the CPPTRAJ module in AmberTools (25). The ligand-
PfKRS1 interaction diagram was prepared using Maestro 11.1 software package (34). Energy 
decomposition analysis was performed using the MMGBSA method as implemented in the 
MMPBSA.py program (35). 
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Figure S5: Modelling of PfKRS1, HsKRS and CpKRS in complex with compound 5.  
(A) left: Overall structure of the dimeric PfKRS1 system and structural details of the PfKRS1 active site 
(cyan), in complex with compound 5 (violet) and lysine (magenta); right: Ligand interaction diagram 
for compound 5 bound in the active site of PfKRS1. (B) left: Representative snapshots of compound 
5 (violet) bound to PfKRS1 active site (transparent cyan) displaying 30 conformations from the MD 
simulations in the presence and absence of lysine (magenta); right: RMSD of compound 5 along the 
MD simulations of PfKRS1 in the presence and absence of lysine. (C) Interactions of compound 5 
(violet) in the active site of HsKRS (green) in the presence of lysine (magenta). (D) Interactions of 
compound 5 (violet) in the active site of CpKRS (orange) in the presence of lysine (magenta). (E) Per-
residue contributions to the binding free energy of compound 5 to PfKRS1 (top), HsKRS (middle) and 
CpKRS (bottom). The decomposition analysis of the binding free energy was performed using MM-
GBSA (see details in Methods section). 
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Figure S6: Differential flexibility of residues near the active site in PfKRS1, HsKRS and CpKRS .  
(A) Distributions from the MD simulations of the distance between Q321 and E339 sidechains in apo 
(blue) and ligand-bound HsKRS (red). (B) RMSD evolution of PfKRS1 R330 (left), HsKRS R323 (middle) 
and CpKRS R295 (right) along the MD simulations in the apo (blue) and ligand-bound (red) states. (C) 
Root mean square fluctuations (RMSF) of individual residues in MD simulations of PfKRS1 (left), HsKRS 
(middle) and CpKRS (right) in the apo (blue) and ligand-bound (red) states 
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Table S4. Summary of MD simulations. 
 
System Simulation 
time (ns) 
 
apo-KRS 
 
apo-PfKRS1 500 
apo-HsKRS 500 
apo-CpKRS 500 
 
KRS in complex with cpd 5 
 
PfKRS1 500 
HsKRS 500 
CpKRS 500 
  
PfKRS1(-Lys) 500 
All the systems were modelled as KRS dimers. All the systems, except PfKRS1(-Lys), also have a bound 
lysine. 
 
 
7. X-ray Crystallography 
 
7.1 PfKRS1 complexes (New Delhi, Dundee) 
Protein:ligand complexes PfKRS1 were obtained by co-crystallisation using methods described 
previously (36).  
 
Briefly PfKRS1 was prepared at 13.5 mg/ml in 50 mM Tris–HCl pH 8.0, 200 mM NaCl, 10 mM 2-
mercaptoethanol. Ligands were prepared at 20mM stock concentration in 100% DMSO before 
addition to protein solution to a final concentration of 400uM. Crystallisation was carried by hanging 
drop vapour diffusion preparing 1µl:1µl drops of protein:reservoir. The reservoir solution consisted 
of 0.1 M Bis-Tris pH 6.5, 2 % (v/v) Tascimate pH 6.0, 20 % (w/v) PEG 3350. Plate shaped crystals were 
obtained after 2-4 weeks incubation at 277 K. 
 
Protein crystals were cryoprotected in mother liquor plus 20% glycerol before freezing in liquid 
nitrogen in preparation for data measurement. Diffraction data were measured at the European 
Synchrotron Radiation Facility (ESRF) beamlines BM14 (PfKRS1;2), ID-29 (PfKRS1:5) and using a 
Rigaku Micromax-007 rotating anode source coupled with a Saturn 944 CCD detector (PfKRS:4). Data 
for PfKRS:2 were integrated, reduced and scaled using HKL2000 (37) with phasing carried out by 
molecular replacement with Phaser (38) as implemented in Phenix (39) using PfKRS1:lys (PDB 4H02) 
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as a search model. The structure was refined using Phenix. Data for PfKRS1:4 and PfKRS1:5 were 
integrated with XDS (40) and reduced and scaled using AIMLESS (41). Phasing was carried out by 
molecular replacement using MOLREP using PfKRS1:lys (PDB 4H02) as a search model. The structure 
was refined using REFMAC5 (42) from the CCCP4 suite of programmes (43). For all PfKRS1 complexes 
manual model alteration was carried out using Coot (44). 
 
7.2 CpKRS complexes (Beryllium Discovery, SSGCID, Dundee) 
To obtain crystals of CpKRS:lys and CpKRS:lys:cladosporin, CpKRS was concentrated to 35 mg/ml and 
incubated with 3 mM MgCl2, L-lysine, and AMPPNP, then mixed 1:1 with a solution containing 25% 
(w/v) PEG-3350, 0.2 M lithium sulfate, 0.1 M Tris base/ HCl, pH 8.5. Crystals were then grown at 289 
K by sitting drop vapor diffusion with 0.4 µl of protein/ligand complex mixed with 0.4 µl reservoir 
solution. Crystals were harvested with 20% ethylene glycol and flash frozen. For CpKRS bound to 
cladosporin and lysine, crystals from the same well were soaked overnight in a solution that is 70% 
of the previous condition, 20% ethylene glycol, 10% DMSO, with 2 mM cladosporin for 24 h, then 
harvested and flash frozen. Crystals of CpKRS:3 were also obtained by soaking methods. CpKRS 
protein was prepared at 35 mg/ml and incubated with 1 mM L-lysine prior to crystallisation by sitting 
drop vapour diffusion. Drops were prepared mixing 1ul protein with 1 µl reservoir solution consisting 
of 25% (w/v) PEG-3350, 0.2 M lithium sulfate, 0.1 M Tris base/ HCl, pH 8.5. Crystals were transferred 
to soaking solution consisting of reservoir solution supplemented with 2 mM 3 prepared from a stock 
solution of 200 mM in DMSO and incubated overnight at 291K. Crystals were passed through a 
cryprotective solution of reservoir solution supplemented with 20% ethylene glycol before flash 
freezing in liquid nitrogen in preparation for data measurement. 
Data for CpKRS:lys and CpKRS:lys:cladosporin were measured beamline 21-ID-F at the Advanced 
Photon Source (APS). Data for CpKRS:3 was measured at beamline I24 at Diamond Light Source (DLS) 
Diffraction data for CpKRS:lys and CpKRS:lys:cladosporin data were processed with XDS and XSCALE 
(40), and data for CpKRS:3 processed with XDS and xia2 (45). The CpKRS:lys structure was determined 
by molecular replacement with Phaser (46) using 3BJU as a starting model. Lysine-bound CpKRS was 
then used as the model to determine the structure of CpKRS:lys:cladosprin. Structure refinement of 
CpKRS:lys and CpKRS:lys:cladosporin was carried out using Phenix (46) and TLS (39) and manual 
model building with Coot. The structure of CpKRS:3 was refined using REFMAC5 (42) with manual 
alteration of all complexes carried out using Coot (44). The quality of all CpKRS structures was 
validated with Molprobity (47).  
 
Data measurement and refinement statistics are shown in Table S5
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 PfKRS1:Lys:2 PfKRS1:5 PfKRS1:4 CpKRS:Lys CpKRS:Lys:Clado CpKRS:Lys:5 
PDB code 6AGT 6HCU 6HCV 5ELN 5ELO 6HCW 
 Data Measurement 
Source ESRF BM14 ESRF ID29 Rigaku 007 APS 21-ID-F APS 21-ID-F DLS I24 
       
Space Group P1 P212121 P212121 P21 P21 P22121 
Unit Cell Dimensions       
a,b,c(Å) 72.8,104.3 100.6 73.2, 95.3, 166.5 73.2,95.3,166.5 72.9,119.5,143.6 73.2, 120.7, 143.3 73.0, 116.5, 142.7 
a,b,g (°) 89.9, 69.6, 61.1 
 
90.0, 90.0, 90.0 
 
90.0,90.0, 90.0 
 
90.0, 90.3, 90.0 
 
90, 90.2, 90 
 
90.0, 90.0, 90.0 
Resolution (Å) 50-1.95 (1.98-
1.95) 
82.75 -1.62 (1.66-
1.62) 
47.73-2.20 (2.26-
2.20) 
50.0–1.90 (1.95–
1.90) 
50.0–1.90 (1.95–
1.90) 
72.94 – 1.46 (1.50-
1.46) 
Observations 725596 636756 286641 734082 803555 1143460 
Unique Observations 166896 148069 59459 192804 194875 205432 
Rmerge (%) 8.5 (68.5) 6.2 (87.2) 11.7 (38.4) 9.5 (55.3) 10.5 (58.7) 7.6 (65.9) 
CC ½ high res 0.922 0.59 0.49 0.83 0.70 0.56 
I/σI 21.7 (2.4) 10 (1.7) 9 (2.3) 12 (2.8) 11 (2.8) 10 (1.4) 
Completeness (%) 96.9 (96.8) 99.9 (100) 98.7 (90.3) 99.7 (99.9) 99.6 (99.9) 97.6 (80.5) 
Redundancy 4.3 (4.4) 4.3 (4.4) 4.8 (2.4) 3.80 (3.80) 4.1 (4.2) 5.6 (2.6) 
 Refinement Statistics 
Resolution Range (Å) 32-1.9 82.75 -1.62 47.73-2.20 19.98–1.90 47.07–1.90 
 
72.94 – 1.46 
R-factor (Rwork/Rfree) 20.3/24.3 18.3/22.6 21.3/25.4 15.4/19.2 20.4/24.6 18.7/21.5 
Number of atoms a 15831/70/84/571 8005/50/47/966 7792/46/-/539 15969/-/87/1942 15928/84/34/1969 8029/28/50/907 
Mean B-factor (Å2) a 45/40/32/38 26/17/38/37 29/20/-/32 26/-/31/33 30/18/83/35 15/10/10/25 
RMS bond length 
deviation (Å) 
0.08 0.02 0.01 0.008 0.01 0.02 
RMS bond angle 
deviation (°) 
1.16 2.24 1.30 0.89 1.07 1.92 
 
Table S5. Data measurement and refinement statistics for KRS complexes.  
Data measurement statistics for the highest resolution shell are shown in parenthesis. a Number of atoms and mean B-factors are shown for 
protein/heteroatom/ligand/water respectively 
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Figure S7: Binding mode of compound 4 with PfKRS1 
Binding mode of 4 (C atoms gold) bound to PfKRS1. H-bonds are shown as dashed lines and key 
residues labelled for clarity 
 
8. Ethical Information 
All NOD SCID gamma mouse studies were performed in compliance with animal care guidelines and 
were approved by the University of Vermont Institutional Animal Care and Use Committee.  The 
University of Vermont is fully accredited by AAALAC (Animal Welfare Assurance Number: D16-00193 
(A3301-01)). 
 
Animal experiments performed at The Art of Discovery were approved by The Art of Discovery 
Institutional Animal Care and Use Committee (TAD-IACUC). This Committee is certified by the Biscay 
County Government (Bizkaiko Foru Aldundia, Basque Country, Spain) to evaluate animal research 
projects from Spanish institutions according to point 43.3 from Royal Decree 53/2013, from the 1st 
of February (BOE-A-2013-1337). All experiments were carried out in accordance with European 
Directive 2010/63/EU. 
 
The animal experiments described here are carried out at the Swiss Tropical and Public Health 
Institute (Basel, Switzerland), adhering to local and national regulations of laboratory animal welfare 
in Switzerland (awarded permission no. 2303). Protocols are regularly reviewed and revised following 
approval by the local authority (Veterinäramt Basel Stadt). 
 
All regulated procedures on living animals in the Drug Discovery Unit, University of Dundee will be 
carried out under the authority of project licence(s) issued by the Home Office under the Animals 
(Scientific Procedures) Act 1986, as amended in 2012 (and in compliance with EU Directive 
EU/2010/63). Licence applications will have been approved by the University's Ethical Review 
Committee (ERC) before submission to the Home Office. The ERC has a general remit to develop and 
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oversee policy on all aspects of the use of animals on University premises and is a sub-committee of 
the University Court, its highest governing body.  
 
The human biological samples were sourced ethically, and their research use was in accord with the 
terms of the informed consents. 
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